Literature DB >> 26411568

Neuroprotective Effect Is Driven Through the Upregulation of CB1 Receptor in Experimental Autoimmune Encephalomyelitis.

Zhi-Yin Lou1, Wen-Bo Yu2, Jie Chen1, Lin Li1, Li-Sheng Jiang3, Bao-Guo Xiao4, Zhen-Guo Liu5.   

Abstract

During immuno-mediated demyelinating lesions, endocannabinoid system participates in both inflammatory and neurodegenerative damage through several mechanisms that involve neuronal and immune cells. Here, we constructed lentiviral vector to upregulate CB1 receptor (CB1R) in the lumbar spinal cord 5-6 region and observe the effect of clinical score and possible mechanism on the occurrence and development of experimental autoimmune encephalomyelitis (EAE). The results show that overexpression of CB1R delayed the onset of clinical signs and ameliorated the severity of disease. Overexpression of CB1R significantly inhibited the expression of NF-kB/p65 and TLR-4 as well as levels of IL-1β, IL-6, and TNF-α, followed by a decrease of IL-17 and an increase of IL-10 in the spinal cord of mice. The percentage of M1 marker CD11b(+)CD16/32(+) cells was decreased, while the percentage of M2 marker CD11b(+)CD206(+) and CD11b(+)IL-10(+) cells was elevated in splenic mononuclear cells (MNCs) of mice with overexpression of CB1R. Interestingly, overexpression of CB1R dramatically enhanced the expression of neurotrophic NT-3, BDNF, and GDNF in the spinal cord. These results indicate that local overexpression of CB1R in the spinal cord exhibited neuroprotective effects in EAE, mainly suppressing inflammatory microenvironment and elevating neurotrophic factors, slightly declining IL-1β and IL-17 in the spleen, and increased IL-10 in the brain. Its complexity remains to be carefully considered and further studied in further investigation.

Entities:  

Keywords:  CB1 receptor; Experimental autoimmune encephalomyelitis; Inflammation; Lentiviral vectors; Neurotrophic factors

Mesh:

Substances:

Year:  2015        PMID: 26411568     DOI: 10.1007/s12031-015-0656-9

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  28 in total

Review 1.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 2.  Disease-modifying treatments for progressive multiple sclerosis.

Authors:  Giancarlo Comi
Journal:  Mult Scler       Date:  2013-10       Impact factor: 6.312

3.  Microglial cell activation and proliferation precedes the onset of CNS autoimmunity.

Authors:  Eugene D Ponomarev; Leah P Shriver; Katarzyna Maresz; Bonnie N Dittel
Journal:  J Neurosci Res       Date:  2005-08-01       Impact factor: 4.164

4.  Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist.

Authors:  Zhi-Yin Lou; Chong-Bo Zhao; Bao-Guo Xiao
Journal:  J Neurosci Res       Date:  2011-09-15       Impact factor: 4.164

Review 5.  Endocannabinoid signalling in Alzheimer's disease.

Authors:  Nazia Maroof; Marie Christine Pardon; David A Kendall
Journal:  Biochem Soc Trans       Date:  2013-12       Impact factor: 5.407

6.  Brain-derived neurotrophic factor controls cannabinoid CB1 receptor function in the striatum.

Authors:  Valentina De Chiara; Francesco Angelucci; Silvia Rossi; Alessandra Musella; Francesca Cavasinni; Cristina Cantarella; Giorgia Mataluni; Lucia Sacchetti; Francesco Napolitano; Maura Castelli; Carlo Caltagirone; Giorgio Bernardi; Mauro Maccarrone; Alessandro Usiello; Diego Centonze
Journal:  J Neurosci       Date:  2010-06-16       Impact factor: 6.167

7.  CB1 cannabinoid receptor agonist inhibits matrix metalloproteinase activity in spinal cord injury: A possible mechanism of improved recovery.

Authors:  Jun Hong; Vijaya Nandiwada; Victoria Jones; Miaomiao Lu; David S Warner; Somnath Mukhopadhyay; Huaxin Sheng
Journal:  Neurosci Lett       Date:  2015-04-14       Impact factor: 3.046

8.  Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia.

Authors:  W Schmidt; F Schäfer; V Striggow; K Fröhlich; F Striggow
Journal:  Neuroscience       Date:  2012-10-13       Impact factor: 3.590

9.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

10.  Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

Authors:  Gareth Pryce; Zubair Ahmed; Deborah J R Hankey; Samuel J Jackson; J Ludovic Croxford; Jennifer M Pocock; Catherine Ledent; Axel Petzold; Alan J Thompson; Gavin Giovannoni; M Louise Cuzner; David Baker
Journal:  Brain       Date:  2003-07-22       Impact factor: 13.501

View more
  3 in total

1.  Mdivi-1, a mitochondrial fission inhibitor, modulates T helper cells and suppresses the development of experimental autoimmune encephalomyelitis.

Authors:  Yan-Hua Li; Fang Xu; Rodolfo Thome; Min-Fang Guo; Man-Luan Sun; Guo-Bin Song; Rui-Lan Li; Zhi Chai; Bogoljub Ciric; A M Rostami; Mark Curtis; Cun-Gen Ma; Guang-Xian Zhang
Journal:  J Neuroinflammation       Date:  2019-07-19       Impact factor: 8.322

2.  Selective Endocannabinoid Reuptake Inhibitor WOBE437 Reduces Disease Progression in a Mouse Model of Multiple Sclerosis.

Authors:  Ines Reynoso-Moreno; Silvia Tietz; Erika Vallini; Britta Engelhardt; Jürg Gertsch; Andrea Chicca
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-26

3.  Inducible Nitric Oxide Synthase Inhibition in the Medial Prefrontal Cortex Attenuates the Anxiogenic-Like Effect of Acute Restraint Stress via CB1 Receptors.

Authors:  Arthur A Coelho; Carla Vila-Verde; Ariandra G Sartim; Daniela L Uliana; Laura A Braga; Francisco S Guimarães; Sabrina F Lisboa
Journal:  Front Psychiatry       Date:  2022-07-14       Impact factor: 5.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.